TrueEval Telehealth Enforcement Index

In the trailing 12 months ending 2026 q2, U.S. regulators logged 104 FDA drug-enforcement actions and 264 DEA controlled-substance actions affecting telehealth-relevant substances (GLP-1s, compounded drugs, hormones, ketamine, peptides). The TrueEval Telehealth Enforcement Index score is 528, up 206% versus the prior 12 months.

Enforcement by substance

• Hormones / testosterone: 47
• GLP-1 (semaglutide/tirzepatide): 44
• Compounded drugs: 9
• Ketamine: 5
• Peptides: 2

Methodology

The TrueEval Telehealth Enforcement Index aggregates official U.S. enforcement data for the substances most relevant to telehealth operators (GLP-1s, compounded drugs, hormones, ketamine, peptides). Source data: the FDA drug-enforcement database via the openFDA API and Drug Enforcement Administration actions via the Federal Register API, both queried live. Score = (Class I recalls × 3) + (Class II × 2) + (Class III × 1) + (DEA controlled-substance actions × 2) over the trailing 12 months. A higher score indicates greater enforcement pressure.